Evidence map›Paper›PMID 40336011›Full record

ArticleGenome medicine2025

Retroelement co-option disrupts the cancer transcriptional programme.

Jane Loong, Rachael Thompson, Callum Hall, Laura Doglio, Judith Pape, Tobias Plowman, George Kassiotis

Abstract read
In one paragraph

Article in Genome medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jane Loong *Retroviral Immunology Laboratory, The Francis Crick Institute, 1 Midland Road, London, NW1 1 AT, UK.
Rachael Thompson *Retroviral Immunology Laboratory, The Francis Crick Institute, 1 Midland Road, London, NW1 1 AT, UK.
Callum HallRetroviral Immunology Laboratory, The Francis Crick Institute, 1 Midland Road, London, NW1 1 AT, UK.
Laura DoglioRetroviral Immunology Laboratory, The Francis Crick Institute, 1 Midland Road, London, NW1 1 AT, UK.
Judith PapeRetroviral Immunology Laboratory, The Francis Crick Institute, 1 Midland Road, London, NW1 1 AT, UK.
Tobias PlowmanRetroviral Immunology Laboratory, The Francis Crick Institute, 1 Midland Road, London, NW1 1 AT, UK.
George KassiotisRetroviral Immunology Laboratory, The Francis Crick Institute, 1 Midland Road, London, NW1 1 AT, UK. george.kassiotis@crick.ac.uk.

Funding

HORIZON EUROPE European Research Council 101018670Wellcome Trust CC2088
6 · The paper itself

Abstract

backgroundTranscriptional activation of otherwise repressed retrotransposable elements (RTEs) is a hallmark of cancer, shaping tumour progression and immunogenicity by multifaceted, yet incompletely understood, mechanisms.

methodsWe used an extended pan-cancer transcriptome assembly to identify potential effects of RTEs on the genes within which they have integrated or those in proximity. These were subsequently verified in test cases by further analysis of transcriptional profiles in cancer patient data, and by in vitro studies involving restoration of gene activity, and proliferation and migration assays in cancer cell lines.

resultsWe report that cancer-specific transcriptional activation of RTEs causes frequent reduction or loss of gene function. Exonisation and alternative splicing of RTEs creates non-functional RNA and protein isoforms and derepressed RTE promoter activity initiates antisense transcription, both at the expense of the canonical isoforms. Contrary to theoretical expectation, transcriptionally activated RTEs affect genes with established tumour-promoting functions, including the common essential RNGTT and the lung cancer-promoting CHRNA5 genes. Furthermore, the disruptive effect of RTE activation on adjacent tumour-promoting genes is associated with slower disease progression in clinical data, whereas experimental restoration of gene activity enhances tumour cell growth and invasiveness in vitro.

conclusionsThese findings underscore the gene-disruptive potential of seemingly innocuous germline RTE integrations, unleashed only by their transcriptional utilisation in cancer. They further suggest that such metastable RTE integrations are co-opted as sensors of the epigenetic and transcriptional changes occurring during cellular transformation and as executors that disrupt the function of tumour-promoting genes.

Indexed as

Gene Expression Regulation, NeoplasticNeoplasmsRetroelementsTranscription, GeneticAlternative SplicingCell Line, TumorCell ProliferationHumansTranscriptional ActivationTranscriptomeRetroelementsCancerIsoform switchingRetrotransposable elementsTranscriptional disruption

Identifiers

PMID40336011
PMCPMC12060413

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.